Vinorelbine Tartrate Oral

DRUG3 trials

Sponsors

Zhiyong Yu, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Pierre Fabre Medicament

Conditions

Advanced Breast CancerFludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast CancerPathologic Residual Cancer Cells

Phase 2

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Zhiyong YuPathologic Residual Cancer Cells

Start: 2018-11-30End: 2025-11-30Target: 200Updated: 2018-10-12

Phase 3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

RecruitingNCT06255392

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer

Start: 2024-06-12End: 2031-03-31Target: 200Updated: 2025-08-15

Unknown Phase

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

RecruitingNCT06500494

Pierre Fabre MedicamentAdvanced Breast Cancer

Start: 2024-09-10End: 2028-02-29Target: 368Updated: 2025-07-24